| 摘要 |
The invention relates to a compound of formula (I) or a salt thereof: wherein: R<SUP>1 </SUP>is C<SUB>1-4</SUB>alkyl, C<SUB>1-3</SUB>fluoroalkyl or -(CH<SUB>2</SUB>)<SUB>2</SUB>OH; R<SUP>2 </SUP>is a hydrogen atom (H), methyl or C<SUB>1</SUB>fluoroalkyl; R<SUP>3a </SUP>is a hydrogen atom (H) or C<SUB>1-3</SUB>alkyl; R<SUP>3 </SUP>is optionally substituted branched C<SUB>3-6</SUB>alkyl, optionally substituted C<SUB>3-8</SUB>cycloalkyl, optionally substituted mono-unsaturated-C<SUB>5-7</SUB>cycloalkenyl, optionally substituted phenyl, or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc): in which n<SUP>1 </SUP>and n<SUP>2 </SUP>independently are 1 or 2; and Y is O, S, SO<SUB>2</SUB>, or NR<SUP>4</SUP>; and wherein Het is of sub-formula (i), (ii), (iii), (iv) or (v): The compounds are phosphodiesterase (PDE) inhibitors, in particular PDE4 inhibitors. Also provided is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a human, for example chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis.
|
